Clinical phenotypes of spinal muscular atrophy patients with hybrid SMN gene

2021 ◽  
Vol 43 (2) ◽  
pp. 294-302
Author(s):  
Emma Tabe Eko Niba ◽  
Hisahide Nishio ◽  
Yogik Onky Silvana Wijaya ◽  
Poh San Lai ◽  
Takenori Tozawa ◽  
...  
1996 ◽  
Vol 97 (3) ◽  
pp. 315-318 ◽  
Author(s):  
Stefania Zappata ◽  
Francesco Tiziano ◽  
Giovanni Neri ◽  
Christina Brahe

2019 ◽  
Vol 14 (3) ◽  
pp. FNL25
Author(s):  
Joseph M Hoolachan ◽  
Emma R Sutton ◽  
Melissa Bowerman

Spinal muscular atrophy (SMA) is a childhood disorder caused by loss of the SMN gene. Pathological hallmarks are spinal cord motor neuron death, neuromuscular junction dysfunction and muscle atrophy. The first SMN genetic therapy was recently approved and other SMN-dependent treatments are not far behind. However, not all SMA patients will reap their maximal benefit due to limited accessibility, high costs and differential effects depending on timing of administration and disease severity. The repurposing of commercially available drugs is an interesting strategy to ensure more rapid and less expensive access to new treatments. In this mini-review, we will discuss the potential and relevance of repositioning drugs currently used for neurodegenerative, neuromuscular and muscle disorders for SMA.


Neurology ◽  
1997 ◽  
Vol 48 (5) ◽  
pp. 1443-1445 ◽  
Author(s):  
E. Bussaglia ◽  
E. F. Tizzano ◽  
I. Illa ◽  
C. Cervera ◽  
M. Baiget

2013 ◽  
Vol 12 (3) ◽  
pp. 3598-3604 ◽  
Author(s):  
W.L. Liu ◽  
F. Li ◽  
Z.X. He ◽  
R. Ai ◽  
H.W. Ma

The Lancet ◽  
1995 ◽  
Vol 346 (8991-8992) ◽  
pp. 1712-1713 ◽  
Author(s):  
Olivier Clermont ◽  
Philippe Burlet ◽  
Suzie Lefebvre ◽  
Lydie Bürglen ◽  
Arnold Munnich ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document